Skip to main content
UltraCon 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Learning Lab Additional Fee
Learning Lab Additional Fee
Learing Lab
Learing Lab
Industry
Industry
Back

Jay D. Pruetz, MD (he/him/his)

Associate Professor of Pediatrics
Cedars Sinai Medical Center
Culver City, United States

Dr. Jay D. Pruetz is a former Associate Professor of Pediatrics and Obstetrics & Gynecology at the University of Southern California (USC) and director of their ‘Fetal Cardiology Program’ in the division of pediatric cardiology at Children’s Hospital Los Angeles (CHLA) from 2010-2024. He graduated Cum Laude from the University of California Los Angeles (UCLA) with a Bachelors of Science in microbiology and molecular genetics in 1996, and graduated Tufts University School of Medicine as Alpha Omega Alpha in 2001. He completed his pediatric internship and residency at Cedars Sinai Medical Center in 2004 and pediatric cardiology fellowship at CHLA in 2008. Dr. Pruetz was board certified in Pediatrics in 2004 and remains subspecialty board certified in Pediatric Cardiology since 2008.

Dr. Pruetz is actively involved in the prenatal detection and perinatal management of fetuses with congenital heart disease. He cares for these infants long after they are born both during their inpatient stay in the hospital and in the outpatient clinic. He is now associate director of the Congenital Heart Program (CHP) at Cedars-Sinai and a representative of the Smidt Heart Institute. His research interests include the study of outcomes for fetuses with critical heart lesions and development of new strategies to improve prenatal and postnatal management.

Dr. Pruetz also has extensive experience in the field of fetal intervention having published mutiple studies on Twin-Twin Transfusion Syndrome, fetal aortic valvuloplasty and congenital heart block. His unique expertise paired with the strength of the CSMC obstetrics/perinatal program will hopefully lead to the development of new and exciting fetal therapies and interventions to treat some of our most complex fetal patients.

Disclosure information not submitted.

Presentation(s):

Email Jay